Oruka Therapeutics (NASDAQ:ORKA) SVP Arjun Agarwal Sells 9,459 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock in a transaction on Friday, June 12th. The stock was sold at an average price of $69.72, for a total transaction of $659,481.48. Following the completion of the transaction, the senior vice president directly owned 17,294 shares in the company, valued at $1,205,737.68. This represents a 35.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30.

Oruka Therapeutics Trading Down 1.5%

NASDAQ ORKA opened at $68.86 on Tuesday. The firm’s fifty day simple moving average is $63.71 and its two-hundred day simple moving average is $44.31. Oruka Therapeutics, Inc. has a 12-month low of $10.77 and a 12-month high of $91.00. The firm has a market capitalization of $4.15 billion, a P/E ratio of -35.49 and a beta of -0.25.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. As a group, sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds have recently made changes to their positions in ORKA. Goldman Sachs Group Inc. acquired a new position in shares of Oruka Therapeutics in the 1st quarter valued at $2,505,000. JPMorgan Chase & Co. increased its position in shares of Oruka Therapeutics by 567.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after acquiring an additional 13,115 shares during the period. Legal & General Group Plc acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $28,000. Rhumbline Advisers acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $320,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $96,000. 56.44% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ORKA. UBS Group lifted their price target on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a report on Monday, April 27th. Wall Street Zen lowered shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reaffirmed a “buy” rating on shares of Oruka Therapeutics in a report on Wednesday, June 3rd. Finally, Stifel Nicolaus upped their target price on Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $131.30.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.